Caplin Point Laboratories Ltd
NSE:CAPLIPOINT

Watchlist Manager
Caplin Point Laboratories Ltd Logo
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Watchlist
Price: 1 862.5 INR 0.53% Market Closed
Market Cap: 141.6B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CAPLIPOINT stock under the Base Case scenario is 1 712.33 INR. Compared to the current market price of 1 862.5 INR, Caplin Point Laboratories Ltd is Overvalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CAPLIPOINT Relative Value
Base Case
1 712.33 INR
Overvaluation 8%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

7.5
P/S
P/S
Price to Sales
7.5
vs History
12
vs Industry
17
Median 3Y
5.5
Median 5Y
4.5
Industry
2.4
Forward
7.1
More Details
27.5
P/E
P/E
Price to Earnings
27.5
vs History
12
vs Industry
15
Median 3Y
21.1
Median 5Y
18.7
Industry
20.3
Forward
26.8
More Details
37.8
P/OCF
P/OCF
Price to OCF
37.8
vs History
30
vs Industry
10
Median 3Y
30.7
Median 5Y
29.5
Industry
15.6
More Details
61.7
P/FCFE
P/FCFE
Price to FCFE
61.7
vs History
34
vs Industry
8
Median 3Y
64.2
Median 5Y
50.6
Industry
23.1
More Details
5.6
P/B
P/B
Price to Book Value
5.6
vs History
15
vs Industry
11
Median 3Y
4.3
Median 5Y
4
Industry
2
More Details
7
EV/S
EV/S
Enterprise Value to Sales
7
vs History
12
vs Industry
17
Median 3Y
5
Median 5Y
4.1
Industry
2.5
Forward
6.7
More Details
11.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.8
vs History
14
vs Industry
16
Median 3Y
9.1
Median 5Y
7.4
Industry
4.8
More Details
21.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
21.4
vs History
12
vs Industry
15
Median 3Y
16.2
Median 5Y
13.3
Industry
12.5
Forward
19.9
More Details
23.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.8
vs History
12
vs Industry
17
Median 3Y
18
Median 5Y
15.2
Industry
15.7
Forward
19
More Details
35.4
EV/OCF
EV/OCF
Enterprise Value to OCF
35.4
vs History
26
vs Industry
10
Median 3Y
28
Median 5Y
26.8
Industry
14.1
More Details
57.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
57.5
vs History
31
vs Industry
8
Median 3Y
57.8
Median 5Y
40.6
Industry
17.6
More Details
7.2
EV/IC
EV/IC
Enterprise Value to IC
7.2
vs History
14
vs Industry
10
Median 3Y
5.7
Median 5Y
5.2
Industry
1.8
More Details

Multiples Across Competitors

CAPLIPOINT Competitors Multiples
Caplin Point Laboratories Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
141.6B INR 7.5 27.5 21.4 23.8
US
Eli Lilly and Co
NYSE:LLY
736.1B USD 15 66.3 35.6 38.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
378.4B USD 4.2 17.4 12.7 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.6 13 14.7
CH
Roche Holding AG
SIX:ROG
211.7B CHF 3.5 25.6 9.6 11.2
CH
Novartis AG
SIX:NOVN
180B CHF 4.1 17 10.1 13.5
UK
AstraZeneca PLC
LSE:AZN
162.9B GBP 3.9 27.9 130.1 196.2
US
Merck & Co Inc
NYSE:MRK
200B USD 3.1 11.5 8.2 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
129.6B USD 2.1 16.4 7.2 10.1
P/E Multiple
Earnings Growth PEG
IN
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Average P/E: 25.5
27.5
17%
1.6
US
Eli Lilly and Co
NYSE:LLY
66.3
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.4
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.6
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.6
32%
0.8
CH
Novartis AG
SIX:NOVN
17
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Average EV/EBITDA: 395.9
21.4
18%
1.2
US
Eli Lilly and Co
NYSE:LLY
35.6
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.6
6%
1.6
CH
Novartis AG
SIX:NOVN
10.1
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.1
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Average EV/EBIT: 1 699.3
23.8
23%
1
US
Eli Lilly and Co
NYSE:LLY
38.9
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
CH
Novartis AG
SIX:NOVN
13.5
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.2
21%
9.3
US
Merck & Co Inc
NYSE:MRK
9.9
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1

See Also

Summary
CAPLIPOINT intrinsic value, competitors valuation, and company profile.
DCF Valuation
CAPLIPOINT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CAPLIPOINT stock valuation using valuation multiples.
Wall Street Estimates
CAPLIPOINT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CAPLIPOINT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.